Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry
Key facts
- Who runs it
- University of California, San Francisco
- Where
- Alpharetta, Austin, Chicago, Dallas, Dover, Durham, Homewood, Irvine, Irving, San Antonio, San Diego, and San Francisco, United StatesSee the 12 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 578 people enrolled
- Started
- May 2014
- Ended
- 30 Jun 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- Radiofrequency ablation of fibroids
- Myomectomy of fibroids
- Record updated
- 27 April 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Planning to undergo or have undergone* RF ablation (Acessa) or myomectomy (laparoscopic or abdominal) for treatment of uterine fibroids
- Able to give informed consent
- Speak English or Spanish; Women enrolled at contracted clinical sites must enroll prior to their RF ablation treatment
Who cannot take part
- <21 years of age
- Plan to undergo hysteroscopic myomectomy
Where in United States
- Fibroid and Pelvic Wellness Center of GeorgiaAlpharetta, United States
- Tassone Advanced GynecologyAustin, United States
- Gynecology Institute of ChicagoChicago, United States
- UT SouthwesternDallas, United States
- Dedicated to WomenDover, United States
- Duke UniversityDurham, United States
- Women's Healthcare Associates of IL, SCHomewood, United States
- UC Irvine Medical CenterIrvine, United States
- MacArthur Medical CenterIrving, United States
- Acacia OBGYNSan Antonio, United States
- University of California San DiegoSan Diego, United States
- University of California San FranciscoSan Francisco, United States
About the trial
What the trial wants to find out
The ULTRA Registry is a nationwide observational arm of the ULTRA trial. Data from the ULTRA Registry will be used to evaluate the long-term safety and efficacy of laparoscopic RF ablation (Acessa).
Read full original descriptionShow less
The ULTRA Registry will recruit women age 21 or older who plan to undergo or have undergone laparoscopic RF ablation (Acessa) or myomectomy within the United States. Participants will be recruited through study materials distributed at clinical offices across the country where gynecologists are performing laparoscopic RF ablation (Acessa). Study participants will consent to participate in a 3 year prospective study conducted by UCSF but the fibroid procedure will be performed by the study participants' own gynecologist. We will evaluate changes in fibroid-related symptoms from pre-treatment values to 6, 12, 18, 24, 30, and 36 months after RFA (Acessa). We will determine long-term efficacy of RFA (Acessa) by evaluating the rate of re-treatment for symptomatic fibroids after the RFA (Acessa) procedure versus myomectomy. Participants will be asked for permission to review their medical records to assess surgical and pregnancy outcomes.
UC San Francisco will have oversight of all scientific and administrative aspects of the study. All study data will be stored securely in a HIPAA compliant, secure database monitored by the UC San Francisco Coordinating Center.
The 2 groups in the trial
- Women undergoing radiofrequency ablation.
Most women (75%) in the trial will be in the group who receive treatment with radiofrequency ablation (Acessa).
Treatment: Radiofrequency ablation of fibroids
- Women undergoing myomectomy
About 25% of women in the trial will be in the group who receive treatment with myomectomy.
Treatment: Myomectomy of fibroids
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Treatment Failure After Laparoscopic Radiofrequency Ablation Compared With Myomectomy.Obstetrics and gynecology, 2026
- Complementary and Alternative Medicine Use Among Women with Symptomatic Uterine Fibroids.Journal of women's health (2002), 2023
- Record updated
- 27 April 2026